ePoster
Switch To Module
Conference Calendar
Digital Evaluations
ePoster
Everything
Everything
Title
Poster Number
Presenter
Author
Filter By
Presentation Topic
Select All
Deselect All
Advanced NSCLC
41
Early stage NSCLC
7
Imaging and staging
3
Locally advanced NSCLC
7
Mesothelioma
3
Metastases to and from the lung
2
Miscellaneous
3
Prevention, Early detection, Epidemiology, Tobacco control
8
SCLC
5
Translational research
10
Tumour biology and pathology
12
Cancel
Clear
Search
Advanced Search
Sign in
ELCC ePoster
Categories
5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma
Tumour biology and pathology
5P - The circular RNA circXPO1 promotes tumor growth in lung adenocarcinoma
Authors
Q. Huang
(Beijing, China)
M. Qiu
(Beijing, China)
Speakers
Q. Huang
(Beijing, China)
Previous Poster
Next Poster
Previous ePoster
4P - Correlation between folate receptor alpha (FRα) expression and clinicopathological features in lung adenocarcinoma
Next ePosters
7P - Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
9P - Clinical validation of an NGS-based assay for detecting multiple genomic alterations in Chinese patients with non-small cell lung cancer
10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations
12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer
13P - The micro-environmental cross talk between mast cells and lung cancer cells through cell-to-cell contact
14P - The characteristics of MET exon 14 skipping mutations in Chinese non-small cell lung cancer: A retrospective analysis
No ePoster preview available
15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor
18P - Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors